1. Home
  2. MTC vs PRLD Comparison

MTC vs PRLD Comparison

Compare MTC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MTC

MMTec Inc.

HOLD

Current Price

$5.33

Market Cap

71.8M

Sector

Technology

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$3.30

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTC
PRLD
Founded
2015
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.8M
69.1M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
MTC
PRLD
Price
$5.33
$3.30
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
29.7K
318.9K
Earning Date
01-01-0001
06-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.21
EPS
N/A
N/A
Revenue
N/A
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
73.43
52 Week Low
$0.25
$0.61
52 Week High
$5.49
$4.19

Technical Indicators

Market Signals
Indicator
MTC
PRLD
Relative Strength Index (RSI) 67.51 60.16
Support Level $0.84 $0.99
Resistance Level N/A $4.19
Average True Range (ATR) 0.40 0.36
MACD 0.05 0.05
Stochastic Oscillator 88.06 54.79

Price Performance

Historical Comparison
MTC
PRLD

About MTC MMTec Inc.

MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: